Inflammatory Myositis in Cancer Patients Receiving Immune Checkpoint Inhibitors

肌炎 医学 内科学 免疫检查点 免疫系统 癌症 癌症研究 免疫学 肿瘤科 免疫疗法
作者
Jeffrey Aldrich,Xerxes Pundole,Sudhakar Tummala,Nicolas L. Palaskas,Clark R. Andersen,Mahran Shoukier,Noha Abdel‐Wahab,Anita Deswal,María E. Suarez‐Almazor
出处
期刊:Arthritis & rheumatology [Wiley]
卷期号:73 (5): 866-874 被引量:116
标识
DOI:10.1002/art.41604
摘要

OBJECTIVE: To estimate the incidence of immune checkpoint inhibitor-related myositis (ICI-myositis) in cancer patients receiving ICIs, and to report associated clinical manifestations, patterns of care, and outcomes. METHODS: We identified a retrospective cohort of patients receiving ICIs between 2016 and 2019 seen at the University of Texas MD Anderson Cancer Center. Cases of ICI-myositis were identified using International Classification of Disease codes and confirmed by reviewing medical records and pathology, as available. RESULTS: A total of 9,088 patients received an ICI. Thirty-six patients (0.40%) were identified as having ICI-myositis: 17 patients (47%) with ICI-myositis alone and 19 (53%) with overlap manifestations (5 patients with myocarditis, 5 with myasthenia gravis, and 9 with both). The incidence of ICI-myositis was 0.31% in those receiving ICI monotherapy and 0.94% in those receiving combination ICI therapy (relative risk 3.1 [95% confidence interval 1.5-6.1]). Twenty-five patients (69%) received ≥1 treatment in addition to glucocorticoids: plasmapheresis in 17 patients (47%), intravenous immunoglobulin in 12 (33%), and biologics in 11 (31%). Patients with overlap conditions had worse outcomes than those with myositis alone, and 79% of them developed respiratory failure. Eight patients died as a result of ICI-myositis, and all had overlap syndrome with myasthenia gravis or myocarditis (P < 0.05); 75% of these patients had a concomitant infection. CONCLUSION: ICI-myositis is a rare but severe adverse event. More than half of the patients presented with overlap manifestations and had deleterious outcomes, including respiratory failure and death. None of the patients with ICI-myositis alone died as a result of adverse events. Optimal treatment strategies have yet to be determined.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
哈哈王完成签到,获得积分10
刚刚
落骛发布了新的文献求助30
刚刚
NexusExplorer的应助被吴军霄采纳,获得10
刚刚
刚刚
海哥哥发布了新的文献求助10
1秒前
1秒前
1秒前
YixiaoWang完成签到,获得积分10
2秒前
今后的应助被youkang采纳,获得10
2秒前
tao完成签到,获得积分10
2秒前
2秒前
泽北发布了新的文献求助10
3秒前
长青发布了新的文献求助10
3秒前
周舟完成签到,获得积分10
4秒前
hyl完成签到,获得积分10
4秒前
李健的应助被布洛芬采纳,获得10
4秒前
4秒前
徐枘发布了新的文献求助10
4秒前
6秒前
晶晶完成签到,获得积分0
6秒前
369ninja发布了新的文献求助10
6秒前
JJBOND发布了新的文献求助10
7秒前
隐形曼青的应助被felix采纳,获得10
7秒前
Wonder罗完成签到,获得积分10
8秒前
9秒前
9秒前
xxv发布了新的文献求助10
9秒前
10秒前
CodeCraft的应助被温羞花采纳,获得10
10秒前
余香的应助被wangyongfang采纳,获得10
12秒前
Lu发布了新的文献求助10
12秒前
13秒前
13秒前
Lemon发布了新的文献求助10
13秒前
13秒前
庸人自扰发布了新的文献求助10
14秒前
方剂小于发布了新的文献求助10
15秒前
樊yuting完成签到 ,获得积分10
15秒前
16秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184267
求助须知:如何正确求助?哪些是违规求助? 9573323
关于积分的说明 21830790
捐赠科研通 7781314
什么是DOI,文献DOI怎么找? 3434307
关于科研通互助平台的介绍 2558389
邀请新用户注册赠送积分活动 2480817